Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01884571 · ClinicalTrials.gov registry record · Phase 2
Immunosuppression in Amyotrophic Lateral Sclerosis (ALS)
A Phase 2 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT01884571 is a Phase 2 study that has completed, run by Emory University. The registered enrollment target is 31 participants.
The verdict
NCT01884571, a Phase 2 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
This is a multicenter, 15-month study evaluating the effect of immunosuppression treatment on the rate of change on the ALS Functional Rating Scale (Revised) (ALSFRS-R) score in up to 33 subjects with Amyotrophic Lateral Sclerosis (ALS).
Interventions
- DRUG Prednisone
- DRUG Methylprednisolone
- DRUG Tacrolimus
- DRUG Mycophenolate mofetil
- DRUG Basiliximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2013-10 |
| Est. Completion | 2016-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01884571
The ClinicalTrials.gov registry entry for NCT01884571 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Prednisone is the first listed.
NCT01884571 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01884571 about?
NCT01884571 is a clinical study titled "Immunosuppression in Amyotrophic Lateral Sclerosis (ALS)". This is a multicenter, 15-month study evaluating the effect of immunosuppression treatment on the rate of change on the ALS Functional Rating Scale (Revised) (ALSFRS-R) score in up to 33 subjects with Amyotrophic Lateral Sclerosis (ALS).
What is the current status of trial NCT01884571?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2013-10. Estimated completion is 2016-01.
What interventions are being tested in trial NCT01884571?
The interventions under investigation include: Prednisone (DRUG), Methylprednisolone (DRUG), Tacrolimus (DRUG), Mycophenolate mofetil (DRUG), Basiliximab (DRUG).
Who is sponsoring clinical trial NCT01884571?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.